Clinical benchmark for healing of chronic venous ulcers

Ross T. Lyon, Frank J. Veith, Laura Bolton, Fidelis Machado, Donald Belsito, John Blebea, Lloyd Cleaver, Anthony Comerota, G. Richard Curl, Herbert Dardik, James Dennis, Bo Eklof, Vincent Falanga, Louis Falo, Duyen Faira, Jay Fisher, Thomas Garland, David Gilepsie, Mitchel Goldman, Adelaide HerbertJamal Hoballah, John Hugill, William Krupski, Benjamin Levy, Joann Lohr, Mark Meissner, James O. Monzoian, William Mullcian, Jeffrey Olin, Tania Phillips, John Porter, John J. Ricotta, Robert Scheinfeld, Anton Sidawy, Ronald Snyder, Stephen Storfer, Jonathon Towne, Robert Weiss, Thomas Whitsett

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


BACKGROUND: To determine the results of standardized ulcer treatment regimes and effects of the oral thromboxane A2 antagonist Ifetroban (250 mg daily) on healing of chronic lower-extremity venous stasis ulcers. METHODS: In a prospective, randomized, double blind, placebo-controlled multicenter study, 165 patients were randomized to Ifetroban (n = 83) versus placebo (n = 82) for a period of 12 weeks. Both groups were treated with sustained graduated compression and hydrocolloid. Ulcer size was measured weekly by tracings and computerized planimetry. A total of 150 patients completed the study. RESULTS: Complete ulcer healing was achieved after 12 weeks in 55% of patients receiving Ifetroban and in 54% of those taking a placebo with no significant differences; 84% of ulcers in both groups achieved greater than 50% area reduction in size. CONCLUSIONS: These results are likely to be useful as a benchmark for comparison with other treatment protocols concerning the care of chronic lower-extremity stasis ulcers.

Original languageEnglish
Pages (from-to)172-175
Number of pages4
JournalAmerican Journal of Surgery
Issue number2
StatePublished - Aug 1998


Dive into the research topics of 'Clinical benchmark for healing of chronic venous ulcers'. Together they form a unique fingerprint.

Cite this